Plain-English translation of NCT02637934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called that may help doctors better detect and understand ovarian, fallopian tube, or peritoneal cancer. The scan uses a small amount of radioactive material to light up cancer cells in your body, similar to a PET scan you may have heard of. Researchers want to understand how the medication works, where it goes in your body, and whether it can help identify cancer more accurately.
Current imaging methods don't always catch all cancer cells or provide enough information about how aggressive a cancer is. This new medication could help doctors see tumors more clearly and better understand which patients might benefit from certain treatments.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the new radioactive medication and then undergo PET/CT imaging scans. Most participants will have one scan that takes images from your neck down to mid-thigh, which typically takes about 30 minutes to an hour. A small group of participants will have multiple scans over about 4 hours to help researchers understand how the medication moves through your body.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States